Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S.

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.

Yet another CRO giant has taken a revenue hit due to a customer demand dip. | Yet another CRO giant has taken a revenue hit ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

While cryptosporidiosis, infection by the protist parasite Cryptosporidium, is rare in the United States, it is a common ...

Shiny new Jade Biosciences has selected its CEO in Tom Frohlich, who co-founded Chinook Therapeutics and served as chief ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

GenSight Biologics is weeks away from running out of money. Again. | GenSight Biologics is weeks away from running out of ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

Lundbeck is slashing the book value of its $250 million Abide Therapeutics buyout in response to phase 1 data that triggered ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...